Skip to main content
Clinical Trials/NCT03157297
NCT03157297
Completed
Phase 1

Micra Atrial Tracking Using a Ventricular Accelerometer Study

Medtronic Cardiac Rhythm and Heart Failure13 sites in 9 countries70 target enrollmentJuly 10, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Atrioventricular Conduction Block
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
70
Locations
13
Primary Endpoint
MARVEL Evolve Substudy
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to characterize performance of the MARVEL algorithm downloaded into the MicraTM TPS to provide atrial synchronous ventricular pacing in subjects with AV block.

A sub-study will be conducted within the Marvel study, the purpose of this study is to characterize the MARVEL algorithm in patients who were enrolled in the MARVEL study, and to collect and compare the accelerometer signals and AV synchrony at a second point in time.

Registry
clinicaltrials.gov
Start Date
July 10, 2017
End Date
November 24, 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has been implanted with, or is expected to be implanted with a MicraTM TPS (Model MC1VR01), with remaining device longevity of 6 years or more.
  • Subject is ≥ 18 years old and as per required local law.
  • Subject has atrioventricular (AV) block.
  • Subject (and/or witness, as applicable per local regulations) provides signed and dated authorization and/or consent per institution and local requirements.
  • Subject is willing and able to comply with the protocol.

Exclusion Criteria

  • Subject is in atrial arrhythmia at the time of enrollment.
  • Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
  • Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to MARVEL study procedures).
  • Subject meets any exclusion criteria required by local law (age or other).
  • Additional criteria for the MARVEL Evolve Sub-study:
  • Inclusion criteria:
  • Subjects in the MARVEL Sub-Study have previously been enrolled in the MARVEL main study

Outcomes

Primary Outcomes

MARVEL Evolve Substudy

Time Frame: Initial 24 hour period after patient enrollment

Characterize the rate of atrioventricular synchrony provided by the MARVEL algorithm and compare the accelerometer signal amplitudes and the AV synchrony provided by the MARVEL algorithm with the data collected during the initial MARVEL procedure.

Atrioventricular synchrony

Time Frame: Initial 24 hour period after patient enrollment

On an individual heartbeat basis, this is defined as a right ventricular paced or sensed R-wave associated with an ECG confirmed P-wave.

Study Sites (13)

Loading locations...

Similar Trials